RBC Capital Maintains Buy Rating on Ocular Therapeutix with $17 Price Target

Ocular Therapeutix (OCUL) received a Buy rating from RBC Capital with a price target of $17.00, according to a report released on August 5. The company's shares closed at $12.50. Ocular Therapeutix also received a Buy rating from Needham's Serge Belanger, while TR | OpenAI reiterated a Hold rating on July 26. Corporate insider activity has been negative, with an increase in insiders selling their shares over the past quarter.

Ocular Therapeutix (OCUL) has seen a mix of analyst ratings and strong support from Raymond James, which reiterated its Strong Buy rating with a $19.00 price target. The company's shares closed at $12.50 on July 2, 2025.

Raymond James highlighted Ocular Therapeutix's encore analyses for Axpaxli in non-proliferative diabetic retinopathy (NPDR), noting that while these results were previously presented, they provide an opportunity to reassess Axpaxli’s potential in this indication and diabetic macular edema (DME). The firm acknowledged that the primary focus for both Ocular Therapeutix and investors remains the SOL-1 readout expected in the first quarter of 2026 for wet age-related macular degeneration (wAMD). Raymond James noted its perspective on Axpaxli in NPDR has evolved from initial skepticism following the first HELIOS data disclosure to a "cautiously constructive" view [1].

On August 5, RBC Capital released a report rating Ocular Therapeutix as a Buy with a $17.00 price target, while Needham's Serge Belanger also gave a Buy rating. However, TR | OpenAI reiterated a Hold rating on July 26. Corporate insider activity has been negative, with an increase in insiders selling their shares over the past quarter.

Ocular Therapeutix reported its first-quarter 2025 earnings, revealing a revenue of $10.6 million, which fell short of analyst expectations of $17.4 million. The company posted a diluted earnings per share of $(0.38), below the projected $(0.30). The revenue decline was linked to factors such as pricing adjustments and changes in stocking patterns for its product Dextenza. Despite these results, several analyst firms have maintained positive ratings on the stock [2].

The company announced it would conclude patient enrollment for the SOL-R trial ahead of schedule, showcasing effective management of clinical trials. The U.S. FDA has indicated that results from the SOL-1 and SOL-R trials could support a potential New Drug Application.

References:
[1] https://za.investing.com/news/analyst-ratings/ocular-therapeutix-stock-maintains-strong-buy-rating-at-raymond-james-93CH-3818555
[2] https://www.biospace.com/press-releases/ocular-therapeutix-reports-second-quarter-2025-financial-results-and-business-highlights